ARCHIVES

FDA Approves Gleevec For First Line Rx Of CML

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: Panel to Meet Jan. 30 In Los Angeles; Fate Of Proposed Urologic Group Depends On Budget

January 10, 1986

Cephalon To Plead Guilty, Pay $425M For Off-Label Marketing.

October 3, 2008

NCI Begins TAILORx Study.

May 26, 2006

Prostate Cancer: NIH Pans To Ramp Up Prostate Cancer Research Funding

June 25, 1999

Clinical Trials: Breast Cancer Prevention Trial requires Fewer Participants, NCI Says

September 6, 1996

Benefits of Mammography Outweigh Harms In Women with Increased Risk, Starting at Age 40

April 27, 2012